U.S. Drug Shortages Hold at 225 Through Third Quarter

The count of active shortages has stayed similar to the past three quarters, according to new industry and regulatory data.

Updated on Nov. 16, 2026 in Healthcare

Isometric editorial illustration of a row of plain amber vials on a bare steel shelf, with empty slots, evoking a steady but strained drug supply.
The U.S. count of active drug shortages held at 225 through the third quarter, with 87 new shortages recorded through September, according to the American Society of Health-System Pharmacists. AI Illustration. Upload story photo >

Live Poll

Do you think prescription drug shortages are getting worse in the U.S.?

Active U.S. drug shortages stood at 225 at the end of the third quarter, a level similar to the past three quarters. The American Society of Health-System Pharmacists reported 87 new shortages through September, nearly matching the 89 it recorded for all of 2025.

Why it matters

Hospitals and patients depend on a steady supply of generic and specialty injectables, and shortages that persist can force clinicians to substitute treatments or delay care. Chemotherapy shortages have lasted longer than drugmakers had estimated for resupply, which raises questions about manufacturer timelines.

The 87 new shortages reported through September nearly equal the 89 logged for all of 2025, indicating a pace that has not slowed. Several discontinuations, including Pfizer's Lincocin multiple-dose vial and Eagle Pharmaceuticals' Belrapzo injection, add to the supply pressure on affected products.

The players

American Society of Health-System Pharmacists

A professional association of pharmacists that tracks and reports drug shortages across U.S. hospitals and health systems.

Pfizer

A major multinational pharmaceutical company that discontinued its 2-milliliter lincomycin vial and a 10-milliliter Lincocin multiple-dose vial.

Eagle Pharmaceuticals

A U.S. specialty pharmaceutical company that is discontinuing its 100-milligram/4-milliliter Belrapzo injection.

Teva Pharmaceuticals

A global generic drugmaker that is discontinuing its propranolol hydrochloride extended-release capsules.

The details

Six drugs were added to FDA shortage and discontinuation listings in November 2026. Eagle Pharmaceuticals is discontinuing its 100-milligram/4-milliliter Belrapzo injection as a business decision, while Teva Pharmaceuticals is ending manufacture of its propranolol hydrochloride extended-release capsules and Ferring Pharmaceuticals is discontinuing its Zomacton somatropin injection.

Timeline

  1. February 2026: Pfizer discontinued its 2-milliliter lincomycin vial.

  2. March 2026: XGen Pharmaceuticals discontinued its lincomycin vials as a business decision.

  3. End of Q3 2026: Active U.S. drug shortages stood at 225.

  4. November 6, 2026: The FDA reported Pfizer's lincomycin discontinuation.

Market Landscape

The 87 new shortages through September nearly match the 89 ASHP recorded for all of 2025, so the 2026 pace is tracking the prior year's level. Shortages in chemotherapy and injectables reflect a supply market where discontinuations and slow resupply continue to outpace recovery.

Patients who rely on affected injectables or oral extended-release capsules may need to ask pharmacists about available alternatives or strengths. Clinicians may substitute therapies, so patients should confirm any change in medication with their prescriber.

The takeaway

Persistent shortages make it worth checking with your pharmacy before a refill if you take a discontinued strength or formulation, since alternatives may require a new prescription.

Further reading

For more on how these supply gaps affect care delivery, explore Healthcare coverage on Wisevoter.

Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.

Live Poll

Do you think prescription drug shortages are getting worse in the U.S.?